Skip to main content
MBI logo

MBI — Investor Relations & Filings

Ticker · 1783 ISIN · TW0001783009 TW Manufacturing
Open in API
Filings indexed 1,694 across all filing types
Latest filing 2024-07-05 Notice of Dividend Amou…
Country TW Taiwan
Listing TW 1783

About MBI

www.mbi.com.tw

Maxigen Biotech Inc. (MBI) is a medical device manufacturer specializing in the research, development, and production of biopolymer-based solutions, primarily focusing on collagen matrix and hyaluronic acid technologies. The company provides a comprehensive range of medical devices across multiple clinical disciplines, including orthopedics, aesthetics, ophthalmology, and wound care. Key products include hyaluronic acid intra-articular injections, dermal fillers, ophthalmic viscoelastics, collagen wound dressings, dental membranes, and synthetic bone grafts. In addition to its proprietary brands, MBI offers global OEM/ODM and customization services. The company adheres to international quality standards, holding certifications such as CE, FDA, NMPA, and MDSAP. MBI leverages its expertise in biopolymer science to deliver innovative medical and skincare products to international markets.

Recent filings

Filing Released Lang Actions
公告本公司決定除息基準日相關事宜
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from a listed company regarding the details of a dividend distribution, including the dividend amount, ex-dividend date, record date, and payment date. It does not contain financial statements or detailed financial analysis but rather provides specific information about dividend payment logistics. This matches the definition of a Notice of Dividend Amount (DIV). The document length is short and focused solely on dividend details, confirming it is not a full report or earnings release.
2024-07-05 Chinese
113年7月變更登記
Share Issue/Capital Change Classification · 95% confidence The document contains detailed information about the company's capital structure, including authorized capital, paid-in capital, capital sources, and changes such as employee stock option conversions. It does not contain financial statements or performance data, nor does it announce a meeting or voting results. The document is a regulatory disclosure about share capital details, which fits best under Share Issue/Capital Change (SHA) category. The document length is short but contains substantive capital change data, not just an announcement of a report. Therefore, it is classified as SHA.
2024-07-04 Chinese
113年年報及股東會資料 — 2024_1783_20240613FE3.pdf
AGM Information Classification · 95% confidence The document is a detailed record of the 2024 Annual Shareholders' Meeting of Maxigen Biotech Inc. It includes attendance details, chairman remarks, management presentations, business reports, audit committee reports, directors' remuneration reports, proposals for ratification including adoption of the 2023 Business Report and Financial Statements, profit distribution, amendments to Articles of Incorporation, election of the Board of Directors, and voting results. The document contains substantive financial data, business reports, audit reports, and governance matters discussed and approved at the meeting. This is characteristic of AGM Information filings, which include presentations and materials shared during the Annual General Meeting. Although it references financial statements and audit reports, these are attachments and part of the AGM materials rather than standalone reports. The document is lengthy (15,000 characters) and contains detailed meeting minutes and voting results, consistent with an AGM Information filing rather than a simple announcement or proxy solicitation. Therefore, the appropriate classification is AGM Information (AGM-R).
2024-06-26 Chinese
113年年報及股東會資料 — 2024_1783_20240613F05.pdf
Annual Report Classification · 95% confidence The document is a detailed record of the 2024 Annual General Meeting (AGM) of 和康生物科技股份有限公司, including the agenda, reports, voting results, and election of directors. It contains the 2023 business report, financial statements, audit committee report, remuneration reports, dividend distribution proposal, amendments to company bylaws, and election results for the board of directors. The document is comprehensive and includes substantive financial data and management reports, not just an announcement or summary. The presence of the full business report, financial statements, audit committee report, and detailed voting results confirms this is the official yearly report covering company activity and full financial performance for the fiscal year 2023. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-06-26 Chinese
113年年報及股東會資料 — 2024_1783_20240613F17.pdf
Major Shareholding Notification Classification · 95% confidence The document contains detailed information about the top ten shareholders, their shareholdings, and relationships among them, including spouse and relatives within two degrees. This type of disclosure is typical of notifications regarding major shareholding changes or ownership structure disclosures. The document is short (1009 characters) and does not contain financial statements or management commentary. It is not an announcement of a report but a direct disclosure of shareholding information. Therefore, the most appropriate classification is Major Shareholding Notification (MRQ).
2024-06-26 Chinese
113年年報及股東會資料 — 2023_1783_20240613FE4.pdf
Annual Report Classification · 100% confidence The document is titled '2023 Annual Report' for Maxigen Biotech Inc. It contains detailed sections typical of an annual report, including a letter to shareholders, company profile, corporate governance report, business capitalization, operational highlights, and comprehensive financial information such as balance sheets, income statements, audit committee review, and consolidated financial statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of detailed financial data and extensive company information confirms this is the official yearly report covering company activity and full financial performance, matching the definition of an Annual Report (10-K). FY 2023
2024-06-26 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.